December 12, 2025

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Exploring the 87.97% Upside Potential

Investors with a keen eye on the healthcare sector might find Treace Medical Concepts, Inc. (NASDAQ: TMCI) an intriguing opportunity, especially in light of its impressive potential upside of 87.97%...

Zevra Therapeutics, Inc. (ZVRA)

⚠️ No article content returned.

..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating Growth Challenges with Strategic Alliances

Investors eyeing the healthcare sector might find Myriad Genetics, Inc. (NASDAQ: MYGN) a compelling yet complex prospect. As a leader in molecular diagnostic testing and precision medicine, Myriad’s portfolio offers..

AngioDynamics, Inc. (ANGO) Poised for Growth: 44% Upside Potential Amid Robust Analyst Ratings

AngioDynamics, Inc. (ANGO), a key player in the healthcare sector, is drawing significant attention from individual investors, thanks to a compelling 43.85% upside potential as suggested by the average target..

Emergent BioSolutions Inc. (EBS) Stock Analysis: Robust Potential Upside Amid Healthcare Challenges

Emergent BioSolutions Inc. (NYSE: EBS) presents an intriguing opportunity for investors, particularly in the healthcare sector. With a current market capitalization of $625.27 million, this Gaithersburg, Maryland-based company operates within..

Prothena Corporation plc (PRTA) Stock Analysis: Biotechnology Innovator with Nearly 97% Potential Upside

Prothena Corporation plc (PRTA), a prominent player in the biotechnology sector, has been making waves with its innovative approaches to treating neurodegenerative diseases. Based in Dublin, Ireland, this late-stage clinical..

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Biotechnology Innovator with 81.55% Potential Upside

Rapport Therapeutics, Inc. (NASDAQ: RAPP), a promising player in the biotechnology sector, has been catching the eye of investors with its ambitious approach to treating central nervous system (CNS) disorders...

Abivax SA (ABVX) Stock Analysis: What Investors Should Know About Its 52-Week High and Analyst Consensus

Abivax SA (ABVX) has captured the attention of investors with a remarkable ascent to its current price of $133.09, marking the peak of its 52-week range, which started at a..

EyePoint Pharmaceuticals (EYPT) Stock Analysis: A 120.5% Upside Potential Amidst Clinical Developments

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biotechnology company dedicated to advancing treatments for serious retinal diseases, presents a captivating opportunity for investors, particularly given the company’s projected potential upside of..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenges with a 7.74% Potential Upside

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a prominent player in the biotechnology sector, specializing in cell programming. Despite its innovative approach and diversified services across various industries, Ginkgo Bioworks..

Celcuity Inc. (CELC) Stock Analysis: Exploring the 5.63% Potential Upside in Biotech Innovation

Celcuity Inc. (CELC), a promising player in the biotechnology sector, is catching the attention of investors following its recent surge in market activity. With a market capitalization of $4.66 billion,..

Standard BioTools Inc. (LAB) Investor Outlook: Navigating Volatility in the Medical Devices Sector

Standard BioTools Inc. (NASDAQ: LAB) presents an intriguing case for investors interested in the healthcare sector, specifically within medical devices. Headquartered in South San Francisco, California, the company is emerging..

Surmodics, Inc. (SRDX): Investor Outlook on Performance Amidst Challenges in Healthcare Sector

Surmodics, Inc. (NASDAQ: SRDX) is a notable player in the healthcare sector, specifically within the medical devices industry. Headquartered in Eden Prairie, Minnesota, the company focuses on performance coating technologies..

MeiraGTx Holdings plc (MGTX) Investor Outlook: Exploring a 215% Potential Upside in the Biotech Sector

MeiraGTx Holdings plc (NASDAQ: MGTX) is capturing the attention of investors with its potential for significant upside, as suggested by a 215% increase in target price. This clinical-stage genetics medicine..

Bioventus Inc. (BVS) Stock Analysis: A 102% Potential Upside in the Medical Devices Sector

Bioventus Inc. (BVS), a notable player in the healthcare sector, provides innovative medical devices aimed at relieving pain and addressing musculoskeletal therapies. With a market capitalization of $496.97 million, Bioventus..

Personalis, Inc. (PSNL) Stock Analysis: Navigating a Challenging Landscape with Strategic Collaborations and Growth Potential

Personalis, Inc. (PSNL), a prominent player in the Healthcare sector, specifically within the Diagnostics & Research industry, offers a suite of cutting-edge cancer genomic tests and services. Headquartered in Fremont,..

Dianthus Therapeutics (DNTH) Stock Analysis: A Biotech Gem with 51.45% Potential Upside

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is catching the eye of investors in the healthcare sector, particularly those with an interest in biotechnology. Founded in 2019 and based in New York,..

Septerna, Inc. (SEPN) Stock Analysis: Exploring a 12,113% Revenue Surge and 11.60% Upside Potential

Septerna, Inc. (SEPN) is capturing the attention of investors in the biotechnology sector with its remarkable 12,113.10% revenue growth and a potential 11.60% upside, according to analysts. As a clinical-stage..

Atai Beckley N.V. (ATAI): Investor Outlook with a 171% Potential Upside and Robust Revenue Growth

Atai Beckley N.V. (NASDAQ: ATAI) emerges as a compelling investment opportunity within the biotechnology sector, particularly for investors keen on the burgeoning field of mental health treatments. Headquartered in Amstelveen,..

Altimmune, Inc. (ALT) Investor Outlook: Exploring a Potential 234% Upside

Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, has captured investor interest with its ambitious pipeline and substantial potential upside. Specializing in treatments for obesity, metabolic, and liver diseases, Altimmune’s lead..

Search

Funds

December 12, 2025

Search

Funds

December 12, 2025

FTSE 100

Funds